Marcelo Do Rego Maciel Souto Maior
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marcelo Do Rego Maciel Souto Maior has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Edmundo Pessoa Lopes
Universidade Federal de Pernambuco, Brazil; Universidade Federal de Pernambuco, Brazil
2 shared publications - Emília Chagas Costa
Universidade Federal de Pernambuco, Brazil
2 shared publications - Hannah Vicentini Vitoriano Silva
Department of Pathology, Federal University of Pernambuco, Recife CEP 50670-901, Brazil
2 shared publications - Nathália de Lacerda Interaminense Ribeiro
Department of Pathology, Federal University of Pernambuco, Recife CEP 50670-901, Brazil
2 shared publications - Bartolomeu Antonio Nascimento Junior
University of Toronto, Toronto, ON, Canada
1 shared publication - Bernardo Schwartz e Mello
Departmento de Cirurgia Plástica, Hospital Israelita Albert Einstein, São Paulo, SP, Brasil
1 shared publication
Latest Publications
- Open Access
- 7 February 2026
- Published by Georg Thieme Verlag KG in Revista Brasileira de Cirurgia Plástica (RBCP) – Brazilian Journal of Plastic Surgery
- Vol. 41 (CP)
Zonas faciais no-touch na técnica do Freelift
Resumo: A técnica Freelift para rejuvenescimento cervicofacial é uma abordagem biplanar, com ampla liberação sub-sistema musculoaponeurótico superficial (SMAS)-platisma; e, portanto, requer conhecimento avançado de anatomia facial e destreza cirúrgica. Descrever a anatomia topográfica das zonas faciais no-touch na cirurgia de Freelift. Estudo prospectivo da anatomia facial por meio de dissecções padronizadas de cadáveres. Os retalhos dermogordurosos e de SMAS-platisma foram inicialmente confeccionados mimetizando o Freelift. Em seguida, foram ampliados para exposição de toda a hemiface. As características topográficas das zonas faciais no-touch foram analisadas. Os pontos de referência para as zonas faciais no-touch foram descritos. Análises histológicas de SMAS foram realizadas. Setenta e quatro famílias foram abordadas, 40 consentiram (54% de taxa de consentimento) em tomar parte do estudo. As hemifaces de 37 cadáveres foram dissecadas. A zona zigomática no-touch inicia-se a 4,5 ± 0,3 cm da incisura supratragal e contém o músculo zigomático maior, o ramo zigomático do nervo facial e o ducto da glândula parótida. As alças superior e inferior do ramo bucal, a gordura bucal e o músculo risório situam-se dentro das zonas bucais no-touch. A zona cervical no-touch mantém os ramos cervicais superiores superficiais a 3,6 ± 0,3 cm do ângulo goníaco. O SMAS móvel é inexistente na histologia. Este estudo com espécimes frescos permitiu a descrição das zonas faciais no-touch na técnica Freelift. Essas zonas contêm estruturas importantes e devem permanecer intactas durante a criação do segmento composto do retalho Freelift. Por fim, a padronização cirúrgica é crucial para realizar a abordagem Freelift com segurança.
- 7 February 2026
- Published by Georg Thieme Verlag KG in Revista Brasileira de Cirurgia Plástica (RBCP) – Brazilian Journal of Plastic Surgery
- Vol. 41 (CP)
Open AccessZonas faciais no-touch na técnica do Freelift
Resumo: A técnica Freelift para rejuvenescimento cervicofacial é uma abordagem biplanar, com ampla liberação sub-sistema musculoaponeurótico superficial (SMAS)-platisma; e, portanto, requer conhecimento avançado de anatomia facial e destreza cirúrgica. Descrever a anatomia topográfica das zonas faciais no-touch na cirurgia de Freelift. Estudo prospectivo da anatomia facial por meio de dissecções padronizadas de cadáveres. Os retalhos dermogordurosos e de SMAS-platisma foram inicialmente confeccionados mimetizando o Freelift. Em seguida, foram ampliados para exposição de toda a hemiface. As características topográficas das zonas faciais no-touch foram analisadas. Os pontos de referência para as zonas faciais no-touch foram descritos. Análises histológicas de SMAS foram realizadas. Setenta e quatro famílias foram abordadas, 40 consentiram (54% de taxa de consentimento) em tomar parte do estudo. As hemifaces de 37 cadáveres foram dissecadas. A zona zigomática no-touch inicia-se a 4,5 ± 0,3 cm da incisura supratragal e contém o músculo zigomático maior, o ramo zigomático do nervo facial e o ducto da glândula parótida. As alças superior e inferior do ramo bucal, a gordura bucal e o músculo risório situam-se dentro das zonas bucais no-touch. A zona cervical no-touch mantém os ramos cervicais superiores superficiais a 3,6 ± 0,3 cm do ângulo goníaco. O SMAS móvel é inexistente na histologia. Este estudo com espécimes frescos permitiu a descrição das zonas faciais no-touch na técnica Freelift. Essas zonas contêm estruturas importantes e devem permanecer intactas durante a criação do segmento composto do retalho Freelift. Por fim, a padronização cirúrgica é crucial para realizar a abordagem Freelift com segurança.
- Open Access
- 17 December 2025
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (1) , 101487
Children with autism spectrum disorder and alterations in eating behavior: could it be gastroesophageal reflux disease?
- 17 December 2025
- Published by Elsevier in Jornal de Pediatria
- Vol. 102 (1) , 101487
Open AccessChildren with autism spectrum disorder and alterations in eating behavior: could it be gastroesophageal reflux disease?
- Open Access
- 4 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2162
Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review
Metabolic dysfunction-associated steatotic liver disease (MASLD)—previously known as non-alcoholic fatty liver disease (NAFLD)—is currently the most common chronic liver disease globally. Observational studies have reported that MASLD is independently associated with extrahepatic disorders, such as chronic kidney disease (CKD). Severe forms of MASLD (i.e., steatohepatitis and liver fibrosis) are even more strongly associated with the risk of incident kidney dysfunction. Hypothetically, MASLD could directly promote CKD through liver-derived endocrine and metabolic mediators, hemodynamic alterations, immune-mediated mechanisms, and oxidative or cellular stress. However, proving that MASLD directly causes CKD is difficult due to the multiple shared cardiometabolic and systemic risk factors, such as obesity, hypertension, and type 2 diabetes mellitus, which serve as confounding variables. Moreover, studies on the association between MASLD and CKD have differed in their designs, sampling methods, disease definitions, and inclusion criteria, precluding more robust evidence supporting a causal relationship. Furthermore, few studies have explored specific issues, such as the new nomenclature for steatotic liver disease, the relationship between these diseases in pediatric populations, the impact of MASLD plus alcohol intake (MetALD) on CKD, and therapeutic options targeting MASLD and CKD simultaneously. Answers to these issues are essential, as the appropriate management of patients with MASLD may prevent or ameliorate kidney dysfunction. The aims of the present study are to describe shared risk factors between MASLD and CKD, the possible direct pathogenic effect of MASLD on kidney structure and function, and gaps in the current literature, to indicate future research directions.
- 4 September 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (9) , 2162
Open AccessMetabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review
Metabolic dysfunction-associated steatotic liver disease (MASLD)—previously known as non-alcoholic fatty liver disease (NAFLD)—is currently the most common chronic liver disease globally. Observational studies have reported that MASLD is independently associated with extrahepatic disorders, such as chronic kidney disease (CKD). Severe forms of MASLD (i.e., steatohepatitis and liver fibrosis) are even more strongly associated with the risk of incident kidney dysfunction. Hypothetically, MASLD could directly promote CKD through liver-derived endocrine and metabolic mediators, hemodynamic alterations, immune-mediated mechanisms, and oxidative or cellular stress. However, proving that MASLD directly causes CKD is difficult due to the multiple shared cardiometabolic and systemic risk factors, such as obesity, hypertension, and type 2 diabetes mellitus, which serve as confounding variables. Moreover, studies on the association between MASLD and CKD have differed in their designs, sampling methods, disease definitions, and inclusion criteria, precluding more robust evidence supporting a causal relationship. Furthermore, few studies have explored specific issues, such as the new nomenclature for steatotic liver disease, the relationship between these diseases in pediatric populations, the impact of MASLD plus alcohol intake (MetALD) on CKD, and therapeutic options targeting MASLD and CKD simultaneously. Answers to these issues are essential, as the appropriate management of patients with MASLD may prevent or ameliorate kidney dysfunction. The aims of the present study are to describe shared risk factors between MASLD and CKD, the possible direct pathogenic effect of MASLD on kidney structure and function, and gaps in the current literature, to indicate future research directions.
- Open Access
- 28 July 2025
- Published by MDPI AG in Preprints.org
Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review
Metabolic dysfunction-associated steatotic liver disease (MASLD) - previously known as nonalcoholic fatty liver disease (NAFLD) - is currently the most common chronic liver disease globally. Observational studies have reported that MASLD is independently associated with extrahepatic disorders, such as chronic kidney disease (CKD). Severe forms of MASLD (i.e. steatohepatitis and liver fibrosis) are even more strongly associated with the risk of incident kidney dysfunction. Hypothetically, MASLD could directly promote CKD through liver-derived endocrine and metabolic mediators, hemodynamic alterations, immune-mediated mechanisms and oxidative or cellular stress. However, proving that MASLD directly causes CKD is difficult due to the multiple shared cardiometabolic and systemic risk factors, such as obesity, hypertension and type 2 diabetes mellitus, which serve as confounding variables. Moreover, studies on the association between MASLD and CKD have differed in their designs, sampling methods, disease definitions and inclusion criteria, precluding more robust evidence supporting a causal relationship. Furthermore, few studies have explored specific issues, such as the new nomenclature for Steatotic Liver Disease, the relationship between these diseases in pediatric populations, the impact of MASLD plus alcohol intake (MetALD) on CKD, and therapeutic options targeting MASLD and CKD simultaneously. Answers to these issues are essential, as the appropriate management of patients with MASLD may prevent or ameliorate kidney dysfunction. The aims of the present study are to describe shared risk factors between MASLD and CKD, the possible direct pathogenic effect of MASLD on kidney structure and function, and gaps in the current literature, to indicate future research directions.
- 28 July 2025
- Published by MDPI AG in Preprints.org
Open AccessMetabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review
Metabolic dysfunction-associated steatotic liver disease (MASLD) - previously known as nonalcoholic fatty liver disease (NAFLD) - is currently the most common chronic liver disease globally. Observational studies have reported that MASLD is independently associated with extrahepatic disorders, such as chronic kidney disease (CKD). Severe forms of MASLD (i.e. steatohepatitis and liver fibrosis) are even more strongly associated with the risk of incident kidney dysfunction. Hypothetically, MASLD could directly promote CKD through liver-derived endocrine and metabolic mediators, hemodynamic alterations, immune-mediated mechanisms and oxidative or cellular stress. However, proving that MASLD directly causes CKD is difficult due to the multiple shared cardiometabolic and systemic risk factors, such as obesity, hypertension and type 2 diabetes mellitus, which serve as confounding variables. Moreover, studies on the association between MASLD and CKD have differed in their designs, sampling methods, disease definitions and inclusion criteria, precluding more robust evidence supporting a causal relationship. Furthermore, few studies have explored specific issues, such as the new nomenclature for Steatotic Liver Disease, the relationship between these diseases in pediatric populations, the impact of MASLD plus alcohol intake (MetALD) on CKD, and therapeutic options targeting MASLD and CKD simultaneously. Answers to these issues are essential, as the appropriate management of patients with MASLD may prevent or ameliorate kidney dysfunction. The aims of the present study are to describe shared risk factors between MASLD and CKD, the possible direct pathogenic effect of MASLD on kidney structure and function, and gaps in the current literature, to indicate future research directions.